Bullish future for KZIA
KZIA Positive Overall Survival in Glioblastoma Study
Kazia expects to present further data in 2H CY2020
Sales in excess of US$ 1 billion per annum treatment for glioblastoma
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.